CDR-Life Inc. (CDR-Life) is a biotechnology company that researches and develops antibody-based therapeutics. The company focuses on compact antibody fragments and multispecific formats, including T-cell engager approaches, to selectively target disease-driving cells and pathways.
CDR-Life advances an internal pipeline from discovery through early development and pursues collaborations and licensing agreements with biopharmaceutical partners to progress its programs. Its work centers on translating proprietary biologics platforms into targeted therapies for serious diseases.
None yet. When a new project in the record names CDR-Life as owner, partner or investor, it shows here.
The agreement expands a successful partnership, focusing on CDR111 to target B cells in autoimmune diseases, with potential payments up to USD 570 million.
